- ¥136bn
- ¥128bn
- ¥19bn
Table: Peptidream -2023 group results (IFRS)
Table: Peptidream -2023 parent results
Table: Peptidream -9-MTH group results (IFRS)
Brief: Peptidream Inc: Received $7.5 Million Milestone Fee From Novartis AG Based On Peptide Drug Conjugate Development Contract
Brief: Peptidream Inc - To Sell About Half Of Its Stake In Rayzebio Inc For $20.9 Million Due To U.S. Company's Nasdaq Listing
Brief: Peptidream Inc: Payment Of Contingent Consideration For Acquisition Of Radiopharmaceutical Business
Table: Peptidream -6-MTH group results (IFRS)
Brief: Astellas And Peptidream Enter Into Research And License Agreement
Brief: Peptidream Inc - Astellas And Peptidream Enter Into Research Collaboration And License Agreement To Discover Novel Targeted Protein Degraders
Brief: Peptidream Inc: Peptidream Announces Achievement Of Milestone In Collaboration With MSD
Table: Peptidream -Q1 group results (IFRS)
Table: Peptidream -2022 group results (IFRS)
Table: Peptidream -2022 parent results
Brief: Peptidream Announces New Research And Collaboration Agreement With Lilly
Brief: Peptidream Announces Collaboration, License Agreement With MSD For Novel Peptide Drug Conjugates
Brief: Peptidream Inc - Announces New Research And Collaboration Agreement With Eli Lilly For The Discovery Of Novel Peptide Drug Conjugates
Brief: Peptidream Inc - Agreed Joint Research And Development, Licensing Deal With Merck Unit MSD For New PDPS Drug Discovery
Brief: Peptidream - Subsidiary PDR Pharma Signs Agreement With Eli Lilly To Jointly Develop Alzheimer's Diagnostic Agent Flortaucipir In Japan
Table: Peptidream -9-MTH group results (IFRS)